Treatments for retinal disease and cancer
Iconic Therapeutics is a clinical-stage biopharmaceutical company dedicated to translating scientific insight into breakthrough medicines. Iconic has a deep understanding of the role of tissue factor (TF) in angiogenesis, inflammation, and metastasis which has led it to develop a new approach to retinal disease and cancer. Their lead product candidate, ICON-1, is a novel immune-conjugate fusion protein. ICON-1 works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of leading causes of blindness.
Are you the next big thing?
We’re a team of VC/PE who are excited about innovative ideas in life sciences. Submit your proposal to us!